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Background: Traditional cancer treatments have centered on cytotoxic drugs and general purpose chemotherapy
that may not be tailored to treat specific cancers. Identification of molecular markers that are related to different types
of cancers might lead to discovery of drugs that are patient and disease specific. This study aims to use microarray
gene expression cancer data to identify biomarkers that are indicative of different types of cancers. Our aim is to
provide a multi-class cancer classifier that can simultaneously differentiate between cancers and identify type-specific
biomarkers, through the application of the Binary Coded Genetic Algorithm (BCGA) and a neural network based
Extreme Learning Machine (ELM) algorithm.
Results: BCGA and ELM are combined and used to select a subset of genes that are present in the Global Cancer
Mapping (GCM) data set. This set of candidate genes contains over 52 biomarkers that are related to multiple cancers,
according to the literature. They include APOA1, VEGFC, YWHAZ, B2M, EIF2S1, CCR9 and many other genes that have
been associated with the hallmarks of cancer. BCGA-ELM is tested on several cancer data sets and the results are
compared to other classification methods. BCGA-ELM compares or exceeds other algorithms in terms of accuracy. We
were also able to show that over 50% of genes selected by BCGA-ELM on GCM data are cancer related biomarkers.
Conclusions: We were able to simultaneously differentiate between 14 different types of cancers, using only 92 genes, to
achieve a multi-class classification accuracy of 95.4% which is between 21.6% and 38% higher than other results in the
literature for multi-class cancer classification. Our findings suggest that computational algorithms such as BCGA-ELM can
facilitate biomarker-driven integrated cancer research that can lead to a detailed understanding of the complexities of
cancer.
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of cancerBackground
Somatic or genetic mutations in key regulatory genes may
cause the molecular machinery to lose control over the
regulation of cell proliferation, differentiation and death
that can in turn lead to clonal proliferation, causing can-
cer. Identification of cancer through morphological fea-
tures of tumor cells has serious limitations since similar
histopathological appearances can imply various clinical
and risk conditions. Recent studies in cancer genomics* Correspondence: bassvasys@hotmail.com
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unless otherwise stated.have created a body of knowledge that has facilitated bet-
ter understanding of the complexities of cancer. Advances
in molecular diagnostics have helped to make cancer clas-
sification that is more objective and precise. The complex-
ity of cancer can be coded in terms of underlying
principles that determine the transformation of normal
cells to cancer cells [1,2].
Biomarkers are measured characteristics of biological
conditions that can indicate favourable or adverse condi-
tions present in cells. Advances in cancer research have re-
vealed that mutational oncogenes and tumor suppressor
genes are molecular markers characteristic of cancer. The
application of computational methods to identify bio-
markers that encode these cancer causing changes canl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vances in the understanding, treatment and prognosis for
cancer.
Microarray data typically consists of thousands of gene
features with only a few hundreds of samples. Computa-
tional biologists have applied Genome wide association
studies using advanced statistical and bioinformatics tech-
niques to better understand the etiology of cancer. Several
studies in gene selection and classification methods have
used the frequently used Global Cancer Mapping (GCM)
[3] microarray gene expression and other cancer data sets
[4-12]. Other improved and efficient methods include
genetic algorithm for gene selection combined with SVM
and fuzzy neural networks [13,14].
In our previous publication, an integer coded genetic algo-
rithm and Extreme Learning Machine (ICGA-ELM) [15]
multiclass approach was used. Other hybrid methods in-
clude particle swarm optimization (BPSO) and genetic algo-
rithm (CGA) [16], an ensemble correlation-based algorithm
with support vector machine [17] and the top scoring genes
(TSG) algorithm [18] among many other studies.
The objective of this study is to select the best set of fea-
tures (genes) that can simultaneously classify different
types of cancers accurately and to help identify bio-
markers. The Binary Coded Genetic Algorithm (BCGA)
combined with the neural network based Extreme Learn-
ing Machine (ELM) is used to obtain high classification
accuracy. BCGA-ELM is tested primarily on the GCM
data set along with several other cancer data sets. These
results are compared to popular classification methods
using the Weka software [19]. BCGA-ELM compares or
exceeds other algorithms (in literature) in terms of accur-
acy. Over 50% of the genes selected by BCGA-ELM are
identified (through IPA analysis) as cancer-related bio-
markers that are closely associated with the hallmarks of
cancer [1,2].
Methods
Several multi-class and binary class microarray data sets
are used in this study. Global Cancer Map (GCM) is pri-
marily used in this study to illustrate the capabilities of the
BCGA-ELM algorithm in selecting cancer related bio-
markers and in obtaining high classification accuracy.
Other cancer data sets are included in this study to show
the robustness and generalization capabilities of BCGA-
ELM in selecting meaningful biomarkers that can achieve
high accuracy, irrespective of the algorithms that are used
for classification.
Data
GCM is an oligonucleotide microarray data obtained from
solid tumors of epithelial origin [3]. GCM data is charac-
terized by a large feature set with a small number of sam-
ples per class. 16063 features (genes) were extracted from190 non-metastasized tumor samples spanning 14 different
types (classes) of common cancers. 77 normal (control)
samples were also included in this study for the binary clas-
sification of cancer vs. tumor. GCM data have a highly im-
balanced data set, where sets of 144 randomly selected
tumor samples that are used for training contain between 8
and 24 samples per class. The remaining 46 tumor samples
that are used for testing contain between 2 and 6 samples
each (Additional file 1: Table S1 and Figure 1). 20 cross-
validated trials were conducted using randomized training
and test sets, where similar sample distributions were main-
tained. From a total of 16063 genes, BCGA-ELM selects a
small set of 92 genes that have the highest discriminatory
power in classifying these cancers. BCGA-ELM was used
for feature selection on other multi-class (Breast, Leukemia
and Lymphoma [20] and binary class (CNS, Colon, DLBCL,
GCM, Lung and Prostate [12]) cancer data sets. These data
are also characterized by large feature sets with very few
samples. The feature sets, number of samples and class in-
formation for these data sets are given in Table 1. Very
small sets of features ranging between 11 and 73 genes are
selected using BCGA-ELM, to classify these cancer sets
with high accuracy.
Ingenuity Pathway Analysis (IPA®) is used to identify bio-
markers among the selected candidate genes for four data
sets (two each for multi-class and binary, as shown in
Table 2). Ingenuity iReport® is used on 190 tumor samples
and 77 normal samples, to compare aggregated tumor-
normal gene expression signatures for each of the 92 genes.
Ingenuity iReport® and IPA® use Ingenuity Knowledge Base®
that has uniquely structured information related to cancer
processes that are experimentally determined to be acti-
vated in cancer cells.Selection of candidate genes using BCGA-ELM
BCGA-ELM consists of the Binary Coded Genetic Algo-
rithm (BCGA) and the fast learning Extreme Learning
Machine (ELM) [21,22]. The genetic algorithm has the
potential to search for the best solution and ELM is cap-
able of accurately classifying sparse data [22].
Genetic algorithm (GA) was developed [23] to design
and build artificial systems that mimic natural systems.
GA that implements the wrapper method, [24,22], are
widely used to solve complex feature selection prob-
lems. In a wrapper method, a machine learning algo-
rithm (such as ELM) continually evaluates different sets
of genes selected by the GA. This hybrid genetic algo-
rithm implements different types of genetic operators,
at different stages of the evolution process, to execute
an effective search and provide the best solution. A
complete survey of genetic algorithms for various com-
plex optimization problems can be found in [25]. We
give a brief description here.
Figure 1 Gene expression for 92 features, selected by BCGA-ELM from GCM dataset (for one of the validation sets of 46 samples). The horizontal
bars for each of the 14 different types of cancers show differentiated gene expression for different cancers, notably for Lymphoma, Leukemia and
CNS, where broad horizontal bars that separate different types of cancers are seen distinctly. The x-axis represents the 92 genes while the y-axis
represents the samples for each type of cancer (see Figure 1 and Additional file 1: Table S2 for gene names and descriptions).
Table 1 Classification accuracy using four multi-class cancer data sets (GCM, Breast, Leukemia, Lymphoma) and six
binary sets (CNS, colon, DLBCL, GCM, lung, prostate) show that performance of BCGA-ELM is superior and consistent
over all these data sets. GCM multi-class has an accuracy of 95.4%, which is at least 21.6% higher than other methods
given in the literature (although some of them use very small sets of genes)
Multi – class Binary-class
Data [3,12,20] GCM Breast Leukemia Lymphoma CNS Colon DLBCL GCM2 Lung Prostate
#Genes-initial set 16063 1213 999 4026 7129 2000 7129 16063 12533 12600
#Genes BCGA-ELM 92 30 11 27 17 27 18 73 11 72
# Samples 198 49 38 96 34 62 77 280 181 102
# Classes 14 4 3 5 2 2 2 2 2 2
Multi-class, Accuracy (%) Binary-class, Accuracy (%)
BCGA-ELM 95.4 100 100 100 100 100 100 100 100 100
(*σ2 = 0.00083)
Weka packages [19]
LibSVM-linear 78.9 100 100 91.9 100 91.9 100 99.1 95.6 97.1
RBF Network 69.8 100 100 82.3 98.7 79.1 96.2 85.4 96.7 93.6
SMO 83.3 100 100 93.6 98.7 89.7 98.7 98.7 95.0 97.1
Naïve Bayes 78.6 100 97.1 72.6 93.5 60.0 81.9 73.1 97.8 92.7
Multiclass Classifier 85.3 100 100 93.6 97.4 93.5 99.8 99.7 94.5 98.8
Method #Genes
ICGA-PSO-ELM [15] 42 88.3 91.2 100 97.0 100 - - - -
HC-k-TSP [8] 5 to 27 67.4 66.7 97.1 - 97.1 90.3 97.4 85.4 97.0
mul-PAM [9] 5 to 27 56.5 93.3 97.1 - 85.3 90.3 92.2 82.9 93.9
BMSF(highest) [10] 5 to 27 - - - - 97.1 95.2 97.4 98.6 100
I-RELIEF(highest)[11] 5 to 27 - - - - 88.4 82.3 95.1 96.1 91.2
LHR(highest) [12] 5 to 27 - - - - 100 91.2 97.4 100 100
Current results show 4.2% improvement over our previous method using ICGA-ELM. All other multi-class and binary data sets are classified with 100% accuracy
(shown in bold). Genes selected by BCGA-ELM (for all data sets) are classified using WEKA [19] machine learning package. These results are much lower for GCM
multi-class data but are fairly consistent for other data sets compared to BCGA-ELM and other results in literature. (*σ is the variance).
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Table 2 Selected Genes, biomarkers and activities related to hallmarks of cancer, as identified by IPA®, for four of the
eight data sets are given here
Data Names of selected genes Biomarkers Hallmarks of Cancer
Breast -
multiclass
CYC1, CYP2A6, DNASE1L3, EEF1D, EVI2A,
GPM6B, HAS1, ICAM3, LAD1, LASP1, LEP,
LMO4, LOC54157, LTBR, NAT1, PFKFB4,
POU2F2, PPP1R1A, RBP1, TCEAL1, TDRD9,
TIMP4
APOE, APOH, BMP7, CALB2, CLU, COL4A3,
EGF, IL4, IL13, ITGAV, LEP, LGALS3BP, LTC4S,
MAPK1, MED21, MTOR, PPARG, PTK2, RBP1,
SLC29A1, SMAD4, STAT5B, TGFB1, THY1,
TIMP4, TLR4, TNF, TREM1
Cell morphology, hematological system
development and function ,cell-to-cell
signalling and interaction, cell death and
survival, cell-mediated immune response,
cellular movement, cellular compromise,





PHF15, SPTAN1, FOXI1, MPO, APOC1, CD33,
PTX3, LSS, ZYX, ATBF1, WIT1
APOC1, CEBPA, JUNB, MPO, NOTCH3, PROC,
ZYX
Hematological system development and
function, immune cell trafficking,
inflammatory response, tissue development,
cellular function and maintenance, cell death
and survival, cell morphology, tissue
morphology, cell-to-cell signalling and inter-
action, cell-to-cell signalling and interaction,




RPS23,TAGLN2, MORC3, BNC1, CSF2,
MCFD2, GTF2B, CORO2A, IGF2BP3, UCHL1,
EEF1B2, CNR2, CSN1S1, ITIH3, (3 unknowns )
CCL2, CCL3L3, CD28, CD44, CDKN1A, CSF2,
ETS1, FASLG, HTT, IGF2BP3, IL2, IL6, IL15,
IL18,STAT3, TLR2, TNF, TREM1, UCHL1
cell cycle arrest, cell death and survival,
cellular compromise, cell-mediated immune
response, cell-to-cell signalling and inter-
action, cellular development, cellular growth




CIRBP, NID2, TRIB2, RPA2, TALDO1, CD28,
ECH1, IQGAP2, CD37, CRYAA, ZFP36L1,
PON1, CCR1, YWHAH, HLA-A (3 unknowns)
B2M, CALR, CCL5, CD28, CSF2, CCR1, CD28,
CD37, CSF2, FLNA, GATA3, HLA-A, IFNG, IL2,
IL5, IL2RG, OPRD1, PDCD1, PPARD, PTGER4,
SLC7A5, TRAF2, YWHAH
cell-to-cell signalling and interaction,
hematological system development and
function, immune cell trafficking,
inflammatory response, cell death and
survival, cellular assembly and organization,
cell cycle arrest, cell death and survival, DNA
replication, recombination, and repair, cell
death and survival, cellular assembly and
organization, cell cycle arrest, cell death and
survival, DNA replication, recombination, and
repair, cell death and survival, cell
morphology survival, cell morphology.
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as a binary string of length 16063, representing the total
number of genes. A '0' in the string indicates exclusion
of the gene in that position and a '1' represents inclusion
of the gene (see Figure 2). In the initialization step, we
generate 200 random binary strings (limited by our com-
putational and time constraints) resulting in the first
population of the 200 solutions. We have used normal-
ized geometric ranking method given in [25,26] for the
selection process. The number of chosen genes are ran-
domly determined (between 20 to 200 genes) in each so-
lution set. Each subset of features is used to compute a
fitness value (see Figure 2) in each of these 200 solu-
tions. A survival of fittest strategy is adopted where
every string is evaluated during each iteration and the
genes that represent the best fit (highest accuracy so far)
are retained. Subsequently, probabilistic genetic opera-
tors (crossover or mutation) are used to create new solu-
tions for the next generation, as shown in Figure 2. The
hybrid crossover operator presented in this study gener-
ates four offspring for each pair of parents by uniform
crossover and two point crossover operators. The mostpromising offspring of the four, substitute their parents
in the population. We use the random mutation oper-
ator to ensure diversity in the population, in order to
overcome the premature convergence and local minima
problems. The fitness of the solution is determined by a
higher mean testing accuracy obtained by the ELM, as









where, ηa is the mean validation accuracy from 20 ran-
dom splits, ωf is the cost of feature selection and d is ex-
pected accuracy. The sum in the denominator counts
the number of 1’s in the string.
The data are divided into training (75%) and testing
(25%) sets randomly. ELM classifier is used to compute
training and testing accuracies. Random splitting and clas-
sification is processed 20 times on each of the 200 binary
strings. Fitness value f (the mean of 20 testing accuracies)
is computed using Equation 1. The final number of genes
Figure 2 Framework of the proposed Binary Coded Genetic Algorithm, which is initialized with a randomly selected set of 200 solutions. These
sets of genes undergo genetic operations such as crossover, mutation and selection, and are continually evaluated by ELM, until the termination
criteria is met (maximum number of iterations or maximum classification accuracy). Computing fitness value f(F,GCM), where F is a binary string,
GCM is a Global Cancer Map data base, f is fitness value computed using Equation 1.
Sachnev et al. BMC Bioinformatics  (2015) 16:166 Page 5 of 12selected (92) is determined by the number of genes
present in the solution set with the highest accuracy. A
20-fold cross-validation of the chosen gene set (repre-
sented by binary string) may guarantee a stable and robust
solution for gene selection.
In our experiments we use ωf = 1 and d = 0.98 in
Equation 1. The process of selecting the best genes con-
tinues during successive generations until the termin-
ation (convergence) criterion (maximum number of
generations or maximum accuracy) is satisfied. In our
experiments we use the following settings for GA: cross-
over probability 80%, mutation probability 20%, selection
probability for normalized geometric ranking method is
q = 1% over 50 generations. Through many iterations and
evaluations, we arrive at a smaller set of 92 genes that sat-
isfies our objective to obtain high accuracy.
The core of the feature selection approach is the ELM
classifier, a fast learning algorithm, which is a single hid-
den layer feed forward neural [21]. In the ELM algo-
rithm, the input weights connecting the input layer and
hidden layer are chosen randomly and output weights
are calculated analytically. ELM evaluates the genes se-
lected by BCGA, in every iteration. The objective of the
ELM classifier is to approximate the decision function
fc : x
t→ yt as accurately as possible. A comprehensive
description of the ELM algorithm is given in [21]. The
simple steps involved in the ELM algorithm can be sum-
marized as follows:
 Given training samples and class labels (Xi,Yi), select
the appropriate activation function and number of
hidden neurons.
 Randomly select the input weights V, bias b and
calculate the output weights W analytically, whereW ¼ YY †h and Y †h is the Moore-Penrose pseudoin-
verse of matrix Yh.
 Use the calculated weights (W, μ, σ) for estimating
the class label in the test set.
 The class label is estimated as the maximum value
of k outputs yki .
c^i ¼ arg maxy
k
i
k ¼ 1; 2;…;C ð2Þ
where arg function returns the class value with the max-
imum output.
ELM can be further improved through proper selection
of ELM parameters (input weights, bias values, and hidden
neurons). This is shown to influence the generalization per-
formance [22,15] of the ELM multiclass classifier favourably
by minimizing the error defined as:
H;V ; bf g ¼ arg min Y−Tf g
H ;V ; b
ð3Þ
where Y is the observed class value and T is the calcu-
lated output value of the class, for a given set of hidden
neurons H and input parameters V and b. The best
weights and bias values for the ELM can be found using
search techniques and optimization methods that are
not very computationally intensive. These parameters
are stored and used later on to determine the class of
new samples.
In this paper we display an overall accuracy as a general
measure of method performance. Overall accuracy is a ra-
tio of number of correctly classified samples to total num-
ber of available samples.
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Discovery of biomarkers by BCGA-ELM
The BCGA-ELM algorithm selects the minimum set of
92 candidate features (from GCM data) that have the
best discriminatory power to differentiate between 14
types of cancers, with 95.4% accuracy (where accuracy is
the proportion of true results, both true positives and
true negatives, among the total number of cases exam-
ined). Figure 1, illustrates the differential expression of
these 92 genes for different types of cancers, for a set of
46 test samples. BCGA-ELM selects smaller sets of fea-
tures, ranging between 11 and 73 genes, from 8 other
cancer data sets which help to classify these cancers with
high accuracy (see Table 1). These data sets with reduced
features, give good results when tested using Weka [19]
packages (using default parameters) illustrating the ro-
bustness and generalization capabilities of BCGA-ELM.
An in-depth, insilico analysis of this data using IPA®
and iReport® show some interesting results. This analysis
indicates that over 52 of the 92 genes are determined to
be significantly differentially expressed genes (DEGs).
Figure 3 and Additional file 1: Table S2 give the full list
of 92 genes with their gene names, description, fold-
change, cell location, type of molecule and biomarker
properties. Additional file 1: Table S3 lists the 52 differ-
entially expressed genes. Top results based on ‘keyword
search for cancer types’ show many of the pathways and
diseases associated with the genes selected by BCGA-
ELM (Additional file 1: Table S4). These genes are
involved in 25 pathways, 66 biological processes, 29
diseases and 3 interactions (see Figure 4 and Additional
file 1: Tables S5 - S6). Additional file 1: Table S7 shows
the top 25 signalling and metabolic pathways in normal
vs. cancer for the selected candidate genes. Additional
file 1: Figure S3 shows the important genes involved in a
network in breast cancer, overlaid with biomarkers,
while Additional file 1: Table S8 shows the top mole-
cules (biomarkers) implicated in Leukemia (as an ex-
ample) as discovered by BCGA-ELM. IPA studies on the
genes selected from the other eight multi-class and bin-
ary data sets yield several biomarkers for each data set.
Table 2 lists the candidate genes, biomarkers and func-
tions related to hallmarks of cancer for four of these
sets.
Discussion
Performance Comparison of BCGA-ELM Classifier with
Existing Methods
Table 1 gives the comparative analysis of results obtained
using the BCGA-ELM approach for GCM and eight other
data sets, We compare our results by running the same
data under the Weka packages [19] and with other
methods reported in the literature (a representative set).
Most of the studies in literature are based on binary orquasi-binary (One Against All) classifications, while our
method employs simultaneous multi-class classification of
the data and gives high classification accuracy. The mini-
mum number of genes required by each method to
achieve maximum generalization performance is also
given.
From Table 1, we can see that the proposed BCGA-
ELM selects a minimum 92 genes (GCM) with a testing
accuracy of 95.4%, which is 4.2% higher than our previous
results. Our results show an increase of 21.6% over the
original Ramaswamy et al. paper [3] for a smaller set of 92
genes, while other studies with small number of genes
have accuracy that are less by 28 to 38% when compared
to our results. The Weka [19] packages give accuracy that
are lesser by 10 to 25.6% (for GCM) when compared to
BCGA-ELM.
The accuracy for multiclass data sets Breast and
Leukemia, with 30 and 11 features respectively, are 100%
for BCGA-ELM and for the Weka algorithms (with a sin-
gle exception for Leukemia which is 97.1% under Naive
Bayes). The results are lower by 33.3% and 6.7% for HC-k-
TSP and mul-PAM respectively (between 5 and 27 fea-
tures) for Breast cancer while they are lesser by 2.9% for
Leukemia. For Lymphoma (using 27 features), BCGA-
ELM achieves 100% while the Weka packages yield be-
tween 72.6% and 93.64%. The lowest results are for Naive
Bayes, which seems to be the general pattern for all data
sets. We have given comparative results for other methods
in the literature only when they are clearly stated as multi-
class computations.
For the six binary data sets (CNS, Colon, DLBCL,
GCM, Lung and Prostate) BCGA-ELM achieves 100%
classification accuracy for all these sets, with reduced fea-
tures ranging between 11 and 92 genes (see Table 1). The
Weka results range on an average between 82.8% and
97.7% for these six data sets where the lowest result is
60% and the highest is 100% with an overall average of
93.1%. These results show the robustness and good
generalization performance for the genes selected by
BCGA-ELM. The results in the literature for these six bin-
ary data sets range on an average between 90% and 97.1%,
where the lowest result is 82.3% and the highest is 100%
with an overall average of 94.3% (except for GCM and
prostate data sets, we have used a comparable number of
genes in our study). Overall, BCGA-ELM exceeds all other
classification algorithms in literature and in Weka, for all
four multi-class and all six binary data sets that are used
in this study, thus illustrating the superior capabilities of
BCGA-ELM.
Although other studies in the literature given in Table 1
achieve similar or comparable accuracies, rarely do those
studies follow up with the biological analysis of the se-
lected genes that relate them directly to cancer. A com-
prehensive list of gene analysis relating selected genes to
Figure 3 Gene names and description for 92 genes selected by BCGA-ELM. Some of the important genes implicated in signalling and metabolic
pathways as determined by IPA® and iReport® analysis are in bold letters.
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Figure 4 The genes that are involved in various cellular activities as indicated by iReport® analysis of the cancer vs. normal data analysis of 92
candidate genes (selected by BCGA-ELM) are displayed inside a wheel here. This figure was consolidated from several figures (given separately in
the supplement) in order to show all cell activities in the same figure. Genes that are involved in cellular activities such as signalling, metabolism,
growth, apoptosis, survival and proliferation, disease specific interaction and signalling pathways are listed here. This wheel displays the most
important 52 candidate genes, where different colours and size of genes indicate various properties. The blue and green colours on the outside
of the big circle represent interactions and pathways. The purple markings are for different processes and the orange outer circles are for different
diseases. Genes are grouped under three major circles for diseases, interaction pathways and processes as indicated by light grey background
circles. The size of the genes indicates the number of diseases/molecular functions/processes they are associated with. Gene circles are coloured
according to their expression levels, which range between −3.304 to 1.637, where blue is for lower values and orange for higher values. The small
blue circles on the south-east corner of the circular gene symbols indicate that these genes have isoforms. There are 103 pathways involving 20
differentially expressed genes (DEGs), 341 processes involving 40 DEGs and 79 diseases involving 29 DEGs. Some of these are illustrated here and
fully listed in Additional file 1: Tables ~ S5 and S6. Genes related to particular types of cancers that are highlighted on the left of the figure are
circled in red. APOPA1, NOTCH2, B2M and VEGFC seem to play major roles in these cancers. Genes responsible for cell death and survival are also
given here.
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In Ramaswamy et al. [3], very few genes (4 out of 98) are
identified as previously known biomarkers. In addition,
they identify some signalling pathway targets that are
statistically significant to certain types of cancers. In our
previous work [15], we found a larger representation of
genes that encode secreted proteins in our candidate
sets, but no biomarkers were identified. The emphasis of
this study is to illustrate that our algorithm is superior
to other methods not only with respect to accuracy but
is also capable of selecting features (genes) that are
closely and directly related to hallmarks of cancer.
In addition to achieving high accuracy, this study high-
lights several biological properties and cancer specific
biomarkers that relate 52 out of 92 of the GCM genes
(more than 50%) to hallmarks of cancer (HC). To our
knowledge, we have not seen such a large selection ofbiomarkers present in the candidate set of genes selected
from the GCM dataset features (using computational
methods). The remaining 40 genes, other than the 52
biomarkers that were identified by IPA® and iReport®,
may be investigated further to determine if they are
related closely to the pathogenesis of cancer. Similarly
Table 2 also lists many of the biomarkers and functions
for the genes selected by BCGA-ELM, from four of the
other eight multi-class and binary data sets. These re-
sults show that BCGA-ELM is capable of selecting fea-
tures that are highly involved in activities related to the
hallmarks of cancer [1,2].
Hallmarks of cancer related to the genes discovered by
BCGA-ELM
Clinical and histopathological data are generally used to
establish the diagnosis and treatment of cancer patients.
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data are not sufficient to make clear diagnosis or propose
treatments. According to Hanahan and Weinberg [1,2],
there are six underlying factors that are responsible for a
cell being transformed from a normal state to a neoplastic
cell, after which the cell ceases to be under the control of
normal body processes. During this multi-step conversion
process, the cancerous cell acquires several biological cap-
abilities that constitute the hallmarks of cancer (HC).
Ingenuity Pathway Analysis® (IPA) and iReport® have
identified 52 differentially expressed genes (DEGs), out
of the 92 genes selected by BCGA-ELM, as known bio-
markers that are closely related to the six hallmarks of
cancer. This type of information can be used for the
diagnosis and treatment of cancer. The expression
changes were interpreted in the context of pathways,
biological processes, disease phenotypes and molecularFigure 5 The top six of twelve biomarkers are listed in this table, with their fa
regulators. Each biomarker is related to multiple cancers, with the top three b
of filling of the circles denotes the number of processes in which the gene is
under biomarker applications indicate the processes or disease related eviden
It can be seen that one biomarker can be active in multiple cancer classes, wi
related to all but pancreatic cancer, while YWHAZ is related to all but ovarian
efficacy of drugs, while some of them are unspecified. Other colour coding ininteractions. These hallmarks include cell processes
such as proliferative signalling (HC1), developing resist-
ance to cell death (HC2), immortalizing cells through
replication (HC3), promoting growth of new blood
vessels (vasculogenesis) to sustain tumors (HC4), invad-
ing healthier tissues (HC5) and promoting spread of
cancer to other parts of the body (HC6). These activities
include self-sufficiency in growth signal, insensitivity to
anti-growth signals, tissue invasion and metastasis, limit-
less replicative potential, sustained angiogenesis and evad-
ing apoptosis.
Figure 4 shows genes that are involved in activities
such as cellular metabolism, growth, death, survival and
proliferation, among others. Additional file 1: Figure S1
shows genes that are responsible for cell death and sur-
vival. Figure 5 shows the top six of twelve biomarkers
that were recognized by Ingenuity® IPA. The molecularmily classification, such as transporters, growth factors, enzymes or
iomarkers are related to almost all but one of the 14 cancers. The degree
involved in. The genes represented as filled circles, in the last column,
ce, such as diagnosis, efficacy, disease progression, prognosis and safety.
th APOA1 involved with all 13 cancers, except CNS. Similarly VEGFC is
cancer. These biomarkers are useful for diagnosis or determining the
this figure are similar to those described in Figure 4.
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given. The biomarkers belong to several biological cat-
egories such as transporters, growth factors, enzymes,
trans-membrane and G-protein coupled receptors and
translation regulators. These biomarkers are used for
several medical applications to help with disease diag-
nosis, testing drug efficacy, measuring disease progres-
sion, disease prognosis and drug safety among others.Figure 6 Hallmarks of cancer genes are listed here. The biological process an
such as cell cycle, death, movement, vasculogenesis, migration, proliferation, t
here. Cell proliferation and migration involves the largest number of genes an
gene, with blue being the lowest and orange or red the highest. The disease
pink circles indicate that the gene is considered as a biomarker, an orange cir
indicate the level of expression, while the green circles (none here) indicate th
under disease state are listed in the second column.Figure 6 gives the list of genes related to some of the can-
cer hallmark processes such as cell cycle, death, movement,
vasculogenesis, migration, proliferation, transport and inva-
sion as identified by Ingenuity iReport®. The nature of the
disease evidence found for each gene is represented by
different colours to indicate if they are biomarkers, muta-
tions or differentially expressed genes where NOTCH2,
EPHB2, YWHAZ, EPHB2, CCL7, B2M, APOPA1, SCAd the genes that are related to some of the cancer hallmark processes
ransport and invasion as identified by Ingenuity iReport®, are shown
d processes. The colour of the circle denotes expression level of each
state/evidence of genes are given by the smaller circles, where the small
cle indicates that the gene is mutated in disease state, the brown circles
at the gene is a drug target. The gene names inside the coloured circles
Sachnev et al. BMC Bioinformatics  (2015) 16:166 Page 11 of 12MP1, VEGFC, PPAP2B, mTOR, IGF and FGF are listed
among others. Additional file 1: Table S9 summarizes the
process counts, disease evidence and neighbour interactions
for all the 52 genes that are of importance in the candidate
gene set.
For the longest time traditional treatments for cancer
centered on cytotoxic drugs and adjuvant therapies lack-
ing precision to treating particular cancers; however, there
is a tremendous shift towards creating therapies focusing
on molecular targets that are rationally designed, aimed to
bring greater efficacy with less harmful side effects.
Conclusion
The proposed BCGA-ELM selects a minimum of 92 target
genes (GCM) with a testing accuracy of 95.4%, which is
between 21.6% and 38% higher than other results in litera-
ture for multi-class cancer classification. The molecular
targets as identified in this study by the BCGA-ELM based
multi-class algorithm has been shown to be reflective of
the hallmarks of cancer [2]. We have used gene expression
analysis to understand what molecular features might be
specific to different types of cancers. The selected genes
present hallmark features that contribute to processes that
might initiate tumors, participate in cell migration and im-
plement invasive properties that facilitate metastasis.
We hope that the BCGA-ELM algorithm can facilitate
biomarker-driven integrated cancer research that can lead
to a detailed understanding of the complexities of cancer.
This understanding can lead to the development of drugs
that are specific to each type of cancer that might be tai-
lored to the needs of individual patients, leading to person-
alized medicine.
Additional file
Additional file 1: Supplement-Multi-class-BCGA-ELM-based-
classiffier-vasily-saras.
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